BeOne Medicines Ltd.
ONC
$308.63
-$5.04-1.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 41.56% | 48.64% | 84.84% | 41.17% | 56.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.56% | 48.64% | 84.84% | 41.17% | 56.09% |
| Cost of Revenue | 16.35% | 32.07% | 54.59% | 106.01% | 517.35% |
| Gross Profit | 85.94% | 51.95% | 91.21% | 32.78% | -32.59% |
| SG&A Expenses | 21.23% | 7.45% | 31.39% | 34.08% | 12.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -105.26% | 105.48% | -- |
| Total Operating Expenses | 18.44% | 9.20% | 23.34% | 38.88% | 13.39% |
| Operating Income | 182.01% | 104.25% | 80.34% | -24.37% | 66.38% |
| Income Before Tax | 193.99% | 108.59% | 79.52% | -162.46% | 71.18% |
| Income Tax Expenses | -63.90% | 154.14% | 417.66% | 8.87% | 5.93% |
| Earnings from Continuing Operations | 178.34% | 100.51% | 58.27% | -175.63% | 68.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 178.34% | 100.51% | 58.27% | -175.63% | 68.41% |
| EBIT | 182.01% | 104.25% | 80.34% | -24.37% | 66.38% |
| EBITDA | 241.18% | 118.01% | 90.73% | -26.98% | 71.94% |
| EPS Basic | 175.71% | 100.49% | 59.13% | -175.81% | 68.43% |
| Normalized Basic EPS | 194.24% | 109.14% | 90.82% | -157.98% | 71.40% |
| EPS Diluted | 166.67% | 100.46% | 59.13% | -175.81% | 67.88% |
| Normalized Diluted EPS | 190.69% | 108.79% | 90.82% | -157.98% | 71.40% |
| Average Basic Shares Outstanding | 3.46% | 2.55% | 2.10% | -0.23% | 0.06% |
| Average Diluted Shares Outstanding | 7.51% | 6.62% | 2.10% | -0.23% | 0.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -2.23% | -- |